08:00 - 08:15 REGISTRATION AND WELCOME

08:15 - 09:00 TNM Staging Session
Chairs:

What we learned from the 9th edition of theTNM and what we expect to learn from the 10th edition 
Nodal dissection: What should surgeons do?
The ITMIG-IASLC nodal map
Q&A, Discussion 

09:00 - 10:00 Recent ITMIG Milestones
Chairs:

ITMIG Standards and Definitions
ITMIG Pathology Guidelines
ITMIG Survey on Clinical and Pathology Practice of the Diagnosis and Treatment of Thymic Epithelial Tumors
ITMIG Postoperative Radiation Therapy (PORT) project 
Q&A, Discussion  

10:00 - 11:00 Oral Abstract Session 1
Chairs:

6 ABSTRACTS PRESENTATIONS 

11:00 - 11:30 Coffee Break

Poster presentations 

11:30 - 12:15 ITMIG-TYME Joint Session
Chairs:

Italian network TYME – Aims and Accomplishments
TETs Italian Registry – Aims and Accomplishments
ITMIG collaboration with national networks and future directions
Q&A, Discussion  

12:15 - 13:00 Bilateral Robotic Thymectomy in Rheumatoid Arthritis: A Multidisciplinary Approach to Complex Surgery.
Case Presentation with Audience Participation
Chairs: 

Presentation with clinical, radiological and pathological comments
Q/A, Discussion

13:00 - 13:45 LUNCH BREAK

SESSION WITH PATIENTS' REPRESENTATIVES

13:45 - 14:45 Management of Recurrent and Re-recurrent Disease
Chairs:

CASE PRESENTATION
Recurrence and primary TETs: Is it the same disease?
Innovative therapies in recurrences of thymic tumors
Round table/audience discussion
The ITMIG recurrence classification: validation and possible updates  

14:45 - 15:45 Anti-angiogenesis, Immunotherapy and Novel Therapies in Thymic Carcinoma
Chairs:

The immunotherapy landscape: from clinical trials to clinical practice
Anti-angiogenics and combinations 
New treatment strategies: Antibody Drug Conjugates and bispecific Antibody Drug Conjugates
Platinum based chemotherapy: still the best option?
Q&A, Discussion 

15:45 - 16:15 Coffee break

Poster presentations 

16:15 - 17:15 Neoadjuvant therapies: When, how and why
Chairs: 

What surgeons need to know from imaging in advanced thymic epithelial tumors?  
Potential neoadjuvant use of immunotherapy and targeted therapy in 2025 
Surgical challenges after neoadjuvant therapy
How to assess pathologic response after neoadjuvant therapy
Q&A, Discussion 

17:15 - 18:15 Nuclear Medicine and Interventional Radiology in TETs - a tailored approach
Chairs:

Prognostic value and role of FDG-PET-CT: Initial staging and after therapy
Beyond FDG
Percutaneous ablation therapy in isolated or multiple extra-mediastinal thymic epithelial lesions: is it worthwhile?
How to manage difficult cases? An Intrapleural recurrence case
Q&A, Discussion

19:00 - 20:00 WELCOME RECEPTION